[6]Buono, G., Gerratana, L., Bulfoni, M., et al. (2019). Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer treatment reviews, 73, 73–83.[7]Gerratana, L., Davis, A. A., Velimirovic, M., et al. (2023). Interplay between ESR1/PIK3CA co...
此前，Breast Cancer Research And Treatment杂志在线发表了一项荟萃分析结果，通过整合既往研究数据，探索了了PIK3CA突变状态在原发性与转移性乳腺癌间的不一致性，该结果对于优化治疗方案、提高治疗效果具有重要意义[6]。医学界特邀江南大学附属医院张颖教授详细解读该研究，现攫取重要内容整理如下，以飨读者。图1 研究标...
基于此背景,Breast Cancer Research杂志近期发表了一项研究,旨在探讨ESR1和PIK3CA变异与肿瘤相关信号通路改变之间的相互关系,并分析这些发现对HR+/HER2-MBC的生物学特征及临床行为的影响,以期为未来的治疗策略提供依据[7]。“医学界”特邀浙江大学医学院附属邵逸夫医院郑和鸣教授详细解读该研究,现攫取重要内容整理如下,以...
[6]Buono, G., Gerratana, L., Bulfoni, M., et al. (2019). Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer treatment reviews, 73, 73–83. [7]Gerratana, L., Davis, A. A., Velimirovic, M., et al. (2023). Interplay between ESR1/PIK3CA ...
此前,Breast Cancer Research And Treatment杂志在线发表了一项荟萃分析结果,通过整合既往研究数据,探索了了PIK3CA突变状态在原发性与转移性乳腺癌间的不一致性,该结果对于优化治疗方案、提高治疗效果具有重要意义[6]。医学界特邀江南大学附属医院张颖教授详细解读该研究,现攫取重要内容整理如下,以飨读者。
G, Kiermaier A, Bianchi GV, et al. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-...
[6]Buono, G., Gerratana, L., Bulfoni, M., et al. (2019). Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer treatment reviews, 73, 73–83. [7]Gerratana, L., Davis, A. A., Velimirovic, M., et al. (2023). Interplay between ESR1/PIK3CA ...
This retrospective cohort study characterizedPIK3CAmutation testing and treatment patterns among HR+/HER2- metastatic breast cancer (mBC) patients in United States (US) community clinical practices.Methods:We used the nationwide Flatiron Health electronic health record-derived de-identified database to ...
FDA approves Genentech’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. News release. Genentech. October 10, 2024. 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国...
此前,Breast Cancer Research And Treatment杂志在线发表了一项荟萃分析结果,通过整合既往研究数据,探索了了PIK3CA突变状态在原发性与转移性乳腺癌间的不一致性,该结果对于优化治疗方案、提高治疗效果具有重要意义[6]。医学界特邀江南大学附属医院张颖教授详细解读该研究,现攫取重要内容整理如下,以飨读者。